Clinical Trial Search

Primary: Difference in Z-score for Rank of Maximum Transverse Diameter (MTD) Regressed on Z-score at Baseline to Assess Growth in Abdominal Aortic Aneurysm MTD Determined by CT…

Primary: Change in the Growth Rate of Abdominal Aortic Aneurysm — 1.77; 1.81; 1.66 mm — p=0.78

Primary: Absence of the Following Procedural Safety Events: Death, Stroke, Myocardial Infarction, Bowel Ischemia, Paraplegia, Respiratory Failure, Renal Failure, Procedural Blood…

Primary: Freedom From Major Adverse Events (MAE) at Day 30 — 3; 4 Participants

Primary: All-cause Mortality — 146; 146 participants — p=0.81

Primary: Annual Aneurysm Growth Rate Between Patients With and Without Micro Bubble Uptake — 3.0; 3.2 mm/year

Primary: Freedom From Aneurysm Rupture — 0 Participants

Primary: Number of Subjects With Proximal Type I Endoleak — 2 Participants

Primary: Time to First Major Adverse Event Experienced by Subjects From the Time of Treatment Through 1 Year — 84.0 days — p=0.003

Primary: Number of Subjects With Aneurysm Volume Increase Greater Than 10% at 2 Years Post-procedure — 9; 31 participants — p=<0.001

Primary: Aix@75 — 31.8; 32.5 percentage

Primary: Freedom From Aneurysm Rupture — 22 Participants

Primary: Primary Safety Endpoint (Freedom From MAEs Within 30 Days of Index Procedure) — 88.6; 96.0 percentage of participants

Primary: Veteran Preference for Repair Type — 25; 25; 95; 80 Participants

Primary: Number of Participants With Proximal Type I Endoleak at Each Timepoint — 1; 0; 0; 0 Participants

Primary: Mortality — 111; 112; 133; 130 Participants

Primary: The Primary Safety Endpoint is Defined as the Percentage of Subjects Who Experience a Major Adverse Event Within 30 Days of the Initial Procedure. — 4 Participants

Primary: Number of Participants Without a Device Related Adverse Events Within 1 Month of the Study Procedure. — 36 Participants

Primary: Number of Participants With Major Adverse Events (MAE) Within 30 Days Postoperative — 1 participants

Primary: Number of Participants With Successful Exclusion of Abdominal Aortic Aneurysm — 49 participants' AAA

Primary: The Number of Patients Who Accepted Inclusion Into a Pre-operative Prehabilitation Programme — 11 participants

Primary: Major Adverse Events at 30 Days — 4; 1; 2 Participants

Primary: Aortic Related Reintervention. — 44; 63 Participants

Primary: Effectiveness: Composite Success Rate — 4 participants

Primary: Number of Subjects With Treatment Success — 58 Participants

Primary: Safety Endpoint: Major Adverse Events (MAEs) — 30 Participants

Primary: Successful Aneurysm Treatment — 90.9; 93.7 percentage of patients

Primary: Rate of Technical Success Through the One Month Follow up. — 54 Participants

Primary: Primary Safety Endpoint — 0; 0; 0; 1 events

Primary: The Number of Subjects Free From a Major Device Event Through 1 Month Post-treatment — 50 participants — p=0.0024